中文名 |
地红霉素 |
---|---|
英文名 |
dirithromycin |
中文别名 |
[9S(R)]-9-脱氧-11-脱氧-9,11-[亚氨[2-(2-甲氧基乙氧基)亚乙基]氧]红霉素 | 布大卡因 | [9S]-9-去氧-11-脱氧-9,11-[亚氨[2-(2-甲氧基乙氧基)亚乙基]氧]红霉素 | [9S(R)]-9-脱氧-11-脱氧-9,11-[亚胺基[2-(2-甲氧基乙氧基)乙叉基]氧基]红霉素 |
英文别名 |
更多 |
描述 |
Dirithromycin(LY 237216)是大环内酯类糖肽抗生素,能与细菌核糖体70S中的50S亚基相结合。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
乙醇:≥50mg / mL(59.88 mM) DMSO:33.33 mg / mL(39.91 mM;需要超声波) * “≥”表示可溶,但饱和度未知。 体内:1。逐个添加每种溶剂:10%EtOH 40%PEG300 5%吐温-80 45%盐水溶解度:≥2.5mg/ mL(2.99mM);澄清溶液2.逐个加入每种溶剂:10%EtOH 90%(20%SBE-β-CD在盐水中)溶解度:≥2.5mg/ mL(2.99mM);澄清溶液3.逐个添加每种溶剂:10%EtOH 90%玉米油溶解度:≥2.5mg / mL(2.99 mM);明确解决方案
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
CC1[C@@]([C@](O)([C@H](OC([C@@H]2C)=O)CC)C)([H])O[C@H](COCCOC)N[C@@]1([H])[C@](C[C@@](O)([C@@H]([C@@H](C)[C@]2([H])O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC)O[C@@](O[C@H](C)C[C@@H]4N(C)C)([H])[C@@H]4O)C)([H])C |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
嘌呤霉素盐酸盐 | G-418 硫酸盐 | 衣霉素 | 潮霉素B | 盐霉素 | 阿维巴坦钠 | 硫酸新霉素 | 法硼巴坦 | 甲氧西林钠 | 利福平 | 甲硝唑 | 羧苄青霉素钠 | 头孢他啶 | Eravacycline dihydrochloride | 头孢噻肟钠 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 871.8±65.0 °C at 760 mmHg |
熔点 | 185 – 189?C |
分子式 | C42H78N2O14 |
分子量 | 835.074 |
闪点 | 481.0±34.3 °C |
精确质量 | 834.545288 |
PSA | 196.33000 |
LogP | 2.84 |
外观性状 | 晶体 |
蒸汽压 | 0.0±0.6 mmHg at 25°C |
折射率 | 1.533 |
分子结构 |
1、 摩尔折射率:217.28 2、 摩尔体积(cm3/mol):691.6 3、 等张比容(90.2K):1854.8 4、 表面张力(dyne/cm):51.7 5、 极化率(10-24cm3):86.13 |
更多 |
从乙醇-水结晶,熔点186~189℃(分解)。pKa9.0(66%二甲基氟化物水溶液)。急性毒性LD50小鼠(g/kg):>1皮下注射,>1口服。 |
符号 |
GHS07 |
---|---|
信号词 |
Warning |
危害声明 |
H317 |
警示性声明 |
P280 |
个人防护装备 |
dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
危害码 (欧洲) |
Xn:Harmful |
风险声明 (欧洲) |
R42/43 |
安全声明 (欧洲) |
S36 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
海关编码 | 29419000 |
下列化合物和2-(2-甲氧基乙氧基)乙醛,在乙醇中于室温下搅拌24h;或者和2-(2-甲氧基乙氧基)乙醛的甲缩醛或乙缩醛,在二氧六环-水中,Dowex 50W存在下,在室温下搅拌6h,均可得到地红霉素。
海关编码 | 29419000 |
---|
The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann. Pharmacother. 26(1) , 46-55, (1992)
To review the chemistry, antimicrobial spectrum, pharmacokinetics, clinical trials, adverse effects, and drug interactions of four new macrolide antibiotics: azithromycin, clarithromycin, dirithromyci…
|
|
Pharmacokinetics of dirithromycin. J. Antimicrob. Chemother. 31 Suppl C , 65-75, (1993)
Dirithromycin is a new member of the macrolide class of antibiotics and has been developed for oral administration. Dirithromycin is a 14-membered lactone ring macrolide and is the C9-oxazine derivati…
|
|
Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin. J. Antimicrob. Chemother. 31 Suppl C , 51-64, (1993)
Polymorphonuclear neutrophils (PMN) play a prominent role in the host response to infectious diseases. One major bactericidal mechanism used by these cells is the production of reactive oxygen species…
|
|
(2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-3-Ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-5-oxo-9-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-4,16-dio xa-14-azabicyclo[11.3.1]heptadec-7-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside |
Noriclan |
Dynabac |
Dirythromycin |
4,16-Dioxa-14-azabicyclo[11.3.1]heptadecan-5-one |
MFCD00865041 |
ASE 136 |
4,16-Dioxa-14-azabicyclo[11.3.1]heptadecan-5-one, 7-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-9- [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)- |
Dirithomycin |
Valodin |
Dirithromycin |
Antibiotic AS-E 136 |